Despite deals being few and far between, as well as the usually slow news flow of the summer months, pharmaceutical news continued to trickle out over the third quarter. Three of BioPharma Dive’s five biggest stories of the July through September period were related to drug pricing in some form — whether that meant finding the right price or what drugs third-party payers preferred.
